Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer

Wei Shou Hwang, Tsu Yi Chao, Shen Fung Lin, Chih Yuan Chung, Chang Fang Chiu, Yi Fang Chang, Po Min Chen, Tzeon Jye Chiou

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC). Fifty-five eligible patients with measurable or assessable M/AGC (median age 62 and 90% of patients presented with metastasis) received oxaliplatin (85mg/m 2) intravenous infusion for 2 h, followed by intravenous infusion of 5-FU (3000 mg/m 2) and leucovorin (100 mg/m 2) for 46h every 14 days until the patient's disease was either in progression, unacceptable toxicity, patient's withdrawal or the investigators' decision to discontinue treatment. Of the 55 enrolled patients, 48 were evaluable for response. Three patients (5.4%) showed complete remission and 20 patients (36.4%) achieved partial response. The overall response rate was 47.9%. Nineteen patients (34.5%) had stable disease and six patients (10.9%) showed progressive disease. The median time to progression was 5.6 months and the median overall survival was 10.8 months. Grade 3/4 toxicities included leucopenia (12.7%), thrombocytopenia (5.4%), diarrhoea (3.6%) and vomiting (9.1%). Peripheral neuropathy was noted in 61.8% of the patients (grade 1/2: 54.5%; grade 3: 7.3%). Our study confirmed that the combination of oxaliplatin and continuous infusion of 5-FU/leucoverin without bolus 5-FU as first-line chemotherapy is active for patients with AGC and relatively safe with lower haematological toxicity.

Original languageEnglish
Pages (from-to)283-288
Number of pages6
JournalAnti-Cancer Drugs
Volume19
Issue number3
DOIs
Publication statusPublished - Mar 2008
Externally publishedYes

Fingerprint

oxaliplatin
Leucovorin
Fluorouracil
Stomach Neoplasms
Drug Therapy
Intravenous Infusions

Keywords

  • Advanced gastric cancer
  • Continuous infusion of 5-fluorouracil/leucovorin
  • Efficacy
  • Oxaliplatin
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. / Hwang, Wei Shou; Chao, Tsu Yi; Lin, Shen Fung; Chung, Chih Yuan; Chiu, Chang Fang; Chang, Yi Fang; Chen, Po Min; Chiou, Tzeon Jye.

In: Anti-Cancer Drugs, Vol. 19, No. 3, 03.2008, p. 283-288.

Research output: Contribution to journalArticle

Hwang, Wei Shou ; Chao, Tsu Yi ; Lin, Shen Fung ; Chung, Chih Yuan ; Chiu, Chang Fang ; Chang, Yi Fang ; Chen, Po Min ; Chiou, Tzeon Jye. / Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. In: Anti-Cancer Drugs. 2008 ; Vol. 19, No. 3. pp. 283-288.
@article{6c52add3af64468496b1c7f2c12da27d,
title = "Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer",
abstract = "This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC). Fifty-five eligible patients with measurable or assessable M/AGC (median age 62 and 90{\%} of patients presented with metastasis) received oxaliplatin (85mg/m 2) intravenous infusion for 2 h, followed by intravenous infusion of 5-FU (3000 mg/m 2) and leucovorin (100 mg/m 2) for 46h every 14 days until the patient's disease was either in progression, unacceptable toxicity, patient's withdrawal or the investigators' decision to discontinue treatment. Of the 55 enrolled patients, 48 were evaluable for response. Three patients (5.4{\%}) showed complete remission and 20 patients (36.4{\%}) achieved partial response. The overall response rate was 47.9{\%}. Nineteen patients (34.5{\%}) had stable disease and six patients (10.9{\%}) showed progressive disease. The median time to progression was 5.6 months and the median overall survival was 10.8 months. Grade 3/4 toxicities included leucopenia (12.7{\%}), thrombocytopenia (5.4{\%}), diarrhoea (3.6{\%}) and vomiting (9.1{\%}). Peripheral neuropathy was noted in 61.8{\%} of the patients (grade 1/2: 54.5{\%}; grade 3: 7.3{\%}). Our study confirmed that the combination of oxaliplatin and continuous infusion of 5-FU/leucoverin without bolus 5-FU as first-line chemotherapy is active for patients with AGC and relatively safe with lower haematological toxicity.",
keywords = "Advanced gastric cancer, Continuous infusion of 5-fluorouracil/leucovorin, Efficacy, Oxaliplatin, Toxicity",
author = "Hwang, {Wei Shou} and Chao, {Tsu Yi} and Lin, {Shen Fung} and Chung, {Chih Yuan} and Chiu, {Chang Fang} and Chang, {Yi Fang} and Chen, {Po Min} and Chiou, {Tzeon Jye}",
year = "2008",
month = "3",
doi = "10.1097/CAD.0b013e3282f3fd17",
language = "English",
volume = "19",
pages = "283--288",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer

AU - Hwang, Wei Shou

AU - Chao, Tsu Yi

AU - Lin, Shen Fung

AU - Chung, Chih Yuan

AU - Chiu, Chang Fang

AU - Chang, Yi Fang

AU - Chen, Po Min

AU - Chiou, Tzeon Jye

PY - 2008/3

Y1 - 2008/3

N2 - This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC). Fifty-five eligible patients with measurable or assessable M/AGC (median age 62 and 90% of patients presented with metastasis) received oxaliplatin (85mg/m 2) intravenous infusion for 2 h, followed by intravenous infusion of 5-FU (3000 mg/m 2) and leucovorin (100 mg/m 2) for 46h every 14 days until the patient's disease was either in progression, unacceptable toxicity, patient's withdrawal or the investigators' decision to discontinue treatment. Of the 55 enrolled patients, 48 were evaluable for response. Three patients (5.4%) showed complete remission and 20 patients (36.4%) achieved partial response. The overall response rate was 47.9%. Nineteen patients (34.5%) had stable disease and six patients (10.9%) showed progressive disease. The median time to progression was 5.6 months and the median overall survival was 10.8 months. Grade 3/4 toxicities included leucopenia (12.7%), thrombocytopenia (5.4%), diarrhoea (3.6%) and vomiting (9.1%). Peripheral neuropathy was noted in 61.8% of the patients (grade 1/2: 54.5%; grade 3: 7.3%). Our study confirmed that the combination of oxaliplatin and continuous infusion of 5-FU/leucoverin without bolus 5-FU as first-line chemotherapy is active for patients with AGC and relatively safe with lower haematological toxicity.

AB - This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC). Fifty-five eligible patients with measurable or assessable M/AGC (median age 62 and 90% of patients presented with metastasis) received oxaliplatin (85mg/m 2) intravenous infusion for 2 h, followed by intravenous infusion of 5-FU (3000 mg/m 2) and leucovorin (100 mg/m 2) for 46h every 14 days until the patient's disease was either in progression, unacceptable toxicity, patient's withdrawal or the investigators' decision to discontinue treatment. Of the 55 enrolled patients, 48 were evaluable for response. Three patients (5.4%) showed complete remission and 20 patients (36.4%) achieved partial response. The overall response rate was 47.9%. Nineteen patients (34.5%) had stable disease and six patients (10.9%) showed progressive disease. The median time to progression was 5.6 months and the median overall survival was 10.8 months. Grade 3/4 toxicities included leucopenia (12.7%), thrombocytopenia (5.4%), diarrhoea (3.6%) and vomiting (9.1%). Peripheral neuropathy was noted in 61.8% of the patients (grade 1/2: 54.5%; grade 3: 7.3%). Our study confirmed that the combination of oxaliplatin and continuous infusion of 5-FU/leucoverin without bolus 5-FU as first-line chemotherapy is active for patients with AGC and relatively safe with lower haematological toxicity.

KW - Advanced gastric cancer

KW - Continuous infusion of 5-fluorouracil/leucovorin

KW - Efficacy

KW - Oxaliplatin

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=45549090652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549090652&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3282f3fd17

DO - 10.1097/CAD.0b013e3282f3fd17

M3 - Article

VL - 19

SP - 283

EP - 288

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -